This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Contents — quick navigation | ||
|---|---|---|
| A | Basic information | ICD-10: G40.4 | Special Copayment Reduction: V233 | Coverage period: 5 years |
| B | Synonyms | Lennox syndrome, myoclonic-atonic epilepsy (distinguished by some) |
| C | Adult onset | Likelihood of first onset in adulthood low — onset at 1~8 years, persists into adulthood, but new onset occurs in childhood |
| S1 | History | The process of establishing the concept of epileptic encephalopathy that began with the work of Lennox and Gastaut |
| S2 | Causes | Cause identifiable in 65~80%, including structural, metabolic, genetic, and unknown |
| S3 | Genetics | Many genes involved, including CDKL5, SCN1A, SCN2A, KCNQ2, ARX |
| S4 | General epidemiology | Prevalence 0.1~0.28/1,000; 1~4% of all childhood epilepsy |
| S5 | Pathophysiology | Cortico-thalamic network abnormality, widespread seizure propagation due to inhibitory–excitatory imbalance |
| S6 | Symptoms | Multiple seizure types (tonic, atonic, atypical absence), cognitive decline, behavioral abnormalities |
| S7 | Signs | Slow spike-wave complexes (<2.5 Hz) on EEG, fast rhythms during sleep, drop attacks |
| S8 | Screening | EEG, neurodevelopmental assessment, metabolic screening |
| S9 | Diagnosis | Clinical diagnosis based on the triad (seizures, EEG, cognition), MRI, gene panel |
| S10 | Treatment | Polytherapy with valproate, clobazam, rufinamide, cannabidiol, etc. |
| S11 | Prognosis | Mostly treatment-refractory; seizures persist into adulthood, cognitive impairment accumulates |
| S12 | Prevention | Fundamental prevention difficult; early diagnosis and treatment of the cause can improve the course |
| S13 | References | 10 key references |
The clinical description of Lennox-Gastaut syndrome (LGS) began in the 1930s~1940s with William Gordon Lennox and his colleague Margaret Lennox. In 1945, Lennox used the term "petit mal variant" while describing a particular seizure pattern associated with toxic encephalopathy. Later, in 1966, the French neurologist Henri Gastaut systematically organized the electroclinical features of this syndrome and presented slow spike-wave (SSW) complexes as the key EEG finding. Gastaut clearly distinguished the characteristic seizure triad of tonic seizures, atonic seizures, and atypical absence seizures, and emphasized that cognitive impairment is an essential element of the syndrome. In honor of this work, the International League Against Epilepsy (ILAE) named the syndrome after both researchers.
In the 1960s~1970s, along with advances in EEG technology, attempts were made to understand LGS as an evolved form of infantile spasms (West syndrome). In fact, about 20~30% of patients with infantile spasms are known to later transition to LGS. In the 1981 ILAE seizure classification and the 1989 classification of epilepsies and epileptic syndromes, LGS was formally classified as an independent developmental epileptic encephalopathy (DEE).
Since the 2000s, with the introduction of next-generation genomic analysis (NGS, whole exome sequencing), the genetic causes of LGS have begun to be identified to a considerable extent. In addition, surgical and non-pharmacological treatments such as the ketogenic diet, vagus nerve stimulation (VNS), and corpus callosotomy were introduced into clinical practice. In 2018, cannabidiol (CBD) received US FDA approval, expanding the pharmacological treatment options for LGS, and in the 2020s clinical studies of deep brain stimulation (DBS) are also under way.
LGS is a heterogeneous syndrome arising from diverse causes. By cause, it is classified as structural, metabolic, genetic, or of unknown cause (idiopathic). The cause is identified in about 65~80% of all patients.
In about 20~35%, the cause cannot be identified with current diagnostic technology. In this case, it is classified as idiopathic LGS or LGS of unclear cause.
LGS is not a disease of a single genetic cause but an electroclinical syndrome arising from diverse genetic and acquired causes. With advances in genomic analysis technology, numerous gene variants are being identified in patients with LGS.
| Gene | Protein/function | Pathogenic mechanism |
|---|---|---|
| SCN1A | Nav1.1 sodium channel | Reduced inhibitory interneuron function (overlaps with Dravet syndrome) |
| SCN2A | Nav1.2 sodium channel | Disruption of excitatory/inhibitory balance |
| KCNQ2 | Kv7.2 potassium channel | Impaired neuronal repolarization |
| CDKL5 | CDKL5 protein kinase | Abnormal synapse formation and dendrite development |
| STXBP1 | Regulation of neurotransmitter release | Synaptic dysfunction |
| ARX | Transcription factor | Abnormal GABAergic interneuron development |
| TSC1/TSC2 | Hamartin/tuberin | mTOR hyperactivation, cortical tuber formation |
Next-generation genomic analysis (whole exome/genome sequencing) shows a diagnostic yield of about 30~50% in patients with LGS. De novo mutations are particularly important and are the main mechanism by which a genetic cause is found in patients without a family history. Tuberous sclerosis complex (TSC) is one of the most common single genetic causes of LGS, with LGS developing in about 30~40% of TSC patients.
Genotype–phenotype correlations are established for some genes, but incomplete penetrance and variable expressivity are observed, with diverse phenotypes appearing even with the same gene variant. Gene panel testing or whole-exome testing is recommended after the diagnosis of LGS to identify the cause and for recurrence counseling.
LGS is a rare epilepsy syndrome occurring worldwide, with an estimated prevalence of about 0.1~0.28 per 1,000 population. It accounts for 1~4% of all childhood epilepsy and is observed at higher proportions in treatment-refractory epilepsy clinics.
The age of onset is typically 1~8 years, with a peak at 3~5 years. It tends to be slightly more common in boys, but the sex difference is not marked. No differences in prevalence by ethnicity have been reported, but differences in access to diagnosis due to socioeconomic factors may affect prevalence estimates.
The rate of transition from West syndrome (infantile spasms) to LGS is known to be about 20~30%. In addition, the incidence is high in patients with preceding conditions such as focal cortical dysplasia, tuberous sclerosis, and hypoxic-ischemic encephalopathy.
In Korea, epidemiological studies based on Health Insurance Review & Assessment Service (HIRA) data include LGS as a major cause of pediatric epileptic encephalopathy, and the number of patients registered for Special Copayment Reduction (V233) is increasing every year. Adult patients are mostly patients whose disease began in childhood and has continued into adulthood; new onset in adults is extremely rare.
The pathophysiology of LGS has not been fully elucidated, but abnormal synchronization of the cortico-thalamic network has been proposed as the key mechanism. The normal cortico-thalamic circuit is essential for sleep–wake cycles and cognitive processing, and in LGS excessive synchronization of this circuit causes widespread seizure propagation.
Reduced function of GABAergic inhibitory interneurons and a relative increase in glutamatergic excitation are observed. In particular, damage to inhibitory networks in the frontal lobe and throughout the cortex is thought to cause multiple seizure types.
Slow spike–slow wave complexes (1.5~2.5 Hz) originate from abnormal oscillation of the cortico-thalamic loop. The alternating inhibitory–excitatory cycle between the reticular nucleus of the thalamus and the cortex is impaired, producing synchronized low-frequency discharges. This is a pathophysiological feature that distinguishes them from the 3 Hz spike-wave of classic absence seizures.
Fast polyspikes occurring during sleep (generalized paroxysmal fast activity, GPFA; ≥10 Hz) are closely associated with tonic seizures. GPFA reflects a hyperexcitable state of the brainstem–cortical pathway and is observed just before the onset of tonic seizures. These sleep EEG findings are an important supportive criterion for the diagnosis of LGS.
Malformations of cortical development, white matter injury, cortical atrophy, and other findings identified on MRI are observed in LGS of structural cause, and these structural abnormalities form the basis for abnormal network formation. In tuberous sclerosis, cortical tubers act as seizure onset sites.
The core clinical features of LGS are the triad of multiple seizure types, cognitive impairment, and behavioral abnormalities.
| Seizure types | Clinical features | Frequency |
|---|---|---|
| Tonic seizure | Sudden muscle tension, generalized stiffening, lasting seconds to tens of seconds; frequent during sleep | Most common |
| Atonic seizure | Falls (drop attacks) due to sudden loss of muscle tone; risk of serious injury | Common |
| Atypical absence seizure | Gradual onset and offset; consciousness partially preserved; tens of seconds to several minutes | Common |
| Myoclonic seizure | Brief muscle contractions; present in some patients | Less common |
| Tonic-clonic seizure | Secondary generalization possible | Some |
Intellectual disability is an essential element of LGS but may not be evident early in the disease. Cognitive function gradually declines over time. Attention deficit, hyperactivity, autism spectrum features, and aggressive behavior may accompany it. Delayed language development and communication disorders are common.
Repeated falls due to atonic and tonic seizures cause physical complications such as head trauma, dental injuries, and fractures. The incidence of status epilepticus is high, and nonconvulsive status epilepticus in particular can be a cause of impaired consciousness.
The clinical signs of LGS are divided into EEG findings and neurological examination findings.
On neurological examination, muscle tone abnormalities (hypotonia or hypertonia), cerebellar signs, pyramidal tract signs, and others are observed variably depending on the underlying disease. Because of repeated falls causing head trauma, there may be evidence of skull fractures, scalp scars, etc. When tuberous sclerosis is the cause, skin findings (ash-leaf spot, shagreen patch, adenoma sebaceum) are observed.
Screening and initial evaluation of LGS proceed in the following steps.
Prolonged video-EEG monitoring including wake and sleep EEG is essential. Confirmation of slow spike–slow wave complexes (1.5~2.5 Hz) and GPFA during sleep is the key to diagnosis. Characteristic findings can be confirmed with interictal EEG alone, but ictal EEG is essential for classifying seizure types.
A comprehensive neuropsychological assessment is needed, including intelligence quotient (IQ) testing, language development assessment, adaptive behavior assessment, and autism spectrum screening tools (M-CHAT, ADOS, etc.).
Analysis of blood and urine metabolites (amino acids, organic acids, ammonia, lactate, etc.) and screening for inborn errors of metabolism are needed to identify the cause. Cerebrospinal fluid testing (glucose, protein, neurotransmitters) is also considered.
The diagnosis of LGS is a clinical diagnosis based on the clinical triad (multiple seizure types, characteristic EEG, cognitive impairment).
Evaluation of structural causes by brain MRI (3T preferred). Malformations of cortical development, corpus callosum abnormalities, tuberous sclerosis lesions, hypoxic-ischemic injury, etc. are identified. PET, fMRI, and MEG are additionally performed when evaluating for surgical treatment.
When the cause is unknown or a genetic cause is suspected, an epilepsy gene panel or whole exome/genome analysis is performed. Simultaneous testing of the parents (trio analysis) is efficient for identifying de novo mutations.
| Disease | Distinguishing points |
|---|---|
| Dravet syndrome | SCN1A mutation, febrile seizures, predominance of myoclonic seizures |
| West syndrome | Infantile spasms, hypsarrhythmia, onset within the first 12 months of life |
| Absence epilepsy | 3 Hz spike-wave, normal cognition, good treatment response |
| CSWS (continuous spike-waves during slow-wave sleep) | Continuous spike-wave during sleep, cognitive regression |
LGS is highly treatment-refractory, so most patients require polytherapy.
LGS mostly shows a treatment-refractory course, and severe neurological damage accumulates over the long term.
About 80% of LGS patients who survive into adulthood are unable to carry out daily living independently and require ongoing medical and social support.
Fundamental prevention of LGS itself is currently impossible. However, the risk of onset can be partly reduced through early diagnosis and treatment of underlying diseases, perinatal management, and the like.
In patients diagnosed with LGS, prevention of secondary complications is important, including seizure monitoring to reduce SUDEP risk (nocturnal seizure detectors, etc.), wearing protective equipment to prevent injuries from falls, and restricting hazardous activities such as swimming and climbing.